Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer Therapy
Women switched to anastrozole treatment have improved event-free survival
December 15th, 2005
Women switched to anastrozole treatment after initial tamoxifen treatment have improved event-free survival. According to researchers from Austria, "Tamoxifen has been the standard adjuvant treatment for postmenopausal women with hormone-responsive early breast cancer for more than 20 years. However, the third-generation aromatase inhibitor anastrozole has proven efficacy and tolerability benefits compared with tamoxifen when used as initial adjuvant therapy." R. Jakesz and colleagues "investigated whether women who have received a period of adjuvant tamoxifen would benefit from being switched to anastrozole. They presented a combined analysis of...
Source: Women's Health Weekly (2005-12-15)
|
